Corona Remedies IPO Analyzed

Key Points

• Company seeks ₹655.3 crore through share sale.
• Strong growth potential in healthcare therapies identified.
• Acquisitions & new facility boost profitability prospects.
• Valuation at 43.5x P/E, attractive for growth.
• Brokerages recommend ‘Subscribe’ with positive outlook.
• GMP indicates strong investor demand prior to listing.

Corona Remedies, a pharmaceutical company based in Gujarat, is opening its initial public offering (IPO) for public subscription on Monday, December 8, 2025. The company wants to raise ₹655.3 crore by selling 6.2 million shares. Importantly, no new money will be raised in this offering.

Analysts, particularly at Arihant Capital, see significant growth for Corona Remedies. They predict this growth will come from focusing on treatments for chronic and women’s health, expanding where the company sells its products, and adding more medicines to its lineup. New factories and purchases will also help the company make more money.

The company is also making plans to grow its team of salespeople and build a new factory for making hormones. These moves are expected to help Corona Remedies grow even further. The price range for the IPO is set between ₹1,008 and ₹1,062 per share. A small investor needs to buy at least 14 shares, which costs around ₹15,000.

Before the IPO’s official listing on the NSE and BSE, which is expected on December 15, 2025, investors have been excited about the company. The unlisted shares were trading at ₹1,427, showing that investors believe the stock will go up in value. This is called a “grey market premium.”

The IPO will run for three days, closing on December 10, 2025. Shareholders will receive their new shares on December 12, 2025. JM Financial, IIFL Capital Services, and Kotak Mahindra Capital Company are helping manage the IPO.

Bigshare Services is the company handling the registration process. Remember, the views and outlooks shared in this article are from the brokerage firms and are not a recommendation to invest. It’s important to do your own research before making any investment decisions.

“Investing in growth requires careful consideration and thorough research.”